Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWP DE-2403
- Development stage
- Unknown
- Lead developer
- Daewoo Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
DWP DE-2403 is an investigational ophthalmic drug candidate being developed by the South Korean pharmaceutical company Daewoo Pharma for the treatment of glaucoma. Currently in Phase 1 clinical development, it is part of Daewoo's specialized "DE" (Daewoo Eye) series of ophthalmic products. While the specific pharmacological mechanism and molecular target have not been publicly disclosed, the drug is intended to address the therapeutic needs of patients with glaucoma, likely through the reduction of intraocular pressure or neuroprotection. It represents one of several candidates in Daewoo Pharma's active glaucoma pipeline, which also includes DWP DE-2302 and DWP DE-2503.
Beyond the preview
Go deeper on DWP DE-2403.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWP DE-2403.